20 - 22 October, 2025
Presented in Japan Standard TimeThe Westin Miyako KyotoDelivered as a Hybrid Event
Dr. Yoshifumi Maya, Ph.D.Group Manager at Nihon Medi-PhysicsSpeaker
Profile
In 2008, Yoshifumi Maya joined Nihon Medi-Physics Co., Ltd., and was engaged in research and development of radiopharmaceuticals. From 2013 to 2015, he belonged to the Department of Nuclear Medicine of University of Wuerzburg, Germany, as a guest scientist. He received a PhD in pharmacy from Chiba University in 2016. Since 2022, he has been working as a group manager at the research center, where he is in charge of non-clinical research on PET diagnostics and Targeted Alpha Therapy products.
Agenda Sessions
Development of NMT25/NMK89 As Theranostics Agents with Novel Platform Technology: 225Ac/89Zr-labeled Antibody Targeting MUC5AC for Pancreatic Cancer
, 11:45View Session